Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Benefit of Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (HCC)

NCT05901194 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05901194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05901194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Benefit of Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (HCC)
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 10, 2024
Completion date
April 30, 2027
Enrollment
25 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable